International Journal of Pharmaceutical Research and Development

ISSN Print: 2664-6862
ISSN Online: 2664-6870
Impact Factor: RJIF 8.55
IJPRD 2025; 7(2): 504-506
www.pharmaceuticaljournal.net
Received: 04-08-2025
Accepted: 07-09-2025

Indrani Anand
Department of Botany, Ramchandra Chandravanshi University, Bishrampur, Palamu, Jharkhand, India

Corresponding Author:
Indrani Anand
Department of Botany, Ramchandra Chandravanshi University, Bishrampur, Palamu, Jharkhand, India

Anti-diabetic potential of Indian medicinal herbs and herbal drugs: An updated evidence review and translational perspective

Indrani Anand

DOI: https://www.doi.org/10.33545/26646862.2025.v7.i2f.212

Abstract
India's rich ethnomedicinal heritage has historically contributed to diabetes management. Modern pharmacological research continues to explore these botanicals as complementary or alternative interventions for type 2 diabetes mellitus (T2DM). This review evaluates key Indian medicinal herbs including *Gymnema sylvestre*, *Curcuma longa*, *Momordica charantia*, *Trigonella foenum-graecum*, *Tinospora cordifolia*, and *Pterocarpus marsupium*. Mechanisms of action, preclinical and clinical evidence, safety profiles, and translational research prospects are discussed. Emphasis is placed on standardization, multicenter clinical trials, and integration with modern pharmacology to develop evidence-based antidiabetic interventions.

Keywords: Ethnomedicinal heritage, type 2 diabetes mellitus (T2DM), Indian medicinal herbs

1. Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, β-cell dysfunction, and impaired glucose homeostasis. India faces an increasing prevalence of diabetes, with approximately 74 million individuals affected, contributing to significant morbidity and healthcare costs. Conventional pharmacotherapy, including metformin, sulfonylureas, and insulin, is effective but often associated with adverse effects such as hypoglycemia, gastrointestinal intolerance, and long-term complications.
Ethnomedicinal knowledge in India, particularly Ayurveda, provides a rich repository of botanicals with hypoglycemic properties. Many of these herbs have been historically used to regulate blood glucose and improve overall metabolic health. Contemporary research seeks to integrate traditional knowledge with scientific validation to develop safer and culturally acceptable interventions.

2. Global Burden of Diabetes
Globally, over 537 million adults live with diabetes, projected to exceed 783 million by 2045. T2DM accounts for approximately 90-95% of cases. The economic burden is substantial, encompassing healthcare costs, loss of productivity, and management of complications such as cardiovascular disease, nephropathy, neuropathy, and retinopathy.
In India, urbanization, sedentary lifestyle, dietary changes, and genetic predisposition contribute to rising prevalence. Effective management strategies are crucial to prevent complications, reduce economic burden, and improve quality of life. Complementary therapies, including herbal interventions, offer potential advantages in terms of safety, affordability, and acceptability.

3. Indian Ethnomedicinal Context
India's biodiversity provides over 1,500 species with documented medicinal properties. Classical Ayurvedic texts describe numerous herbs for glycemic control. Key herbs include:

- ***Gymnema sylvestre* (Gurmar):** Traditionally used to suppress sugar cravings and regulate blood glucose.
- ***Curcuma longa* (Turmeric):** Known for anti-inflammatory and antioxidant properties.

- ***Momordica charantia* (Bitter Gourd):** Used as a dietary supplement for glycemic control.
- ***Trigonella foenum-graecum* (Fenugreek):** Seeds contain bioactive compounds that improve insulin sensitivity.
- ***Tinospora cordifolia* (Guduchi):** Immune-modulating and antioxidative herb.
- ***Pterocarpus marsupium* (Indian Kino Tree):** Known for β-cell protective activity.

Ethnobotanical surveys confirm the widespread use of these herbs in rural and urban populations for diabetes management. Contemporary pharmacology investigates their molecular mechanisms and therapeutic efficacy.

4. Mechanisms of Action of Anti-diabetic Herbs

- **β-cell regeneration and protection:** Certain compounds stimulate pancreatic β-cells, enhancing insulin secretion and survival.
- **Peripheral insulin sensitization:** Activation of AMPK and PPAR-γ pathways improves glucose uptake in muscle and adipose tissue.
- **Inhibition of carbohydrate-digesting enzymes:** α-amylase and α-glucosidase inhibition slows glucose absorption.
- **Reduction of oxidative stress and inflammation:** Antioxidants neutralize free radicals, protecting pancreatic cells.
- **Upregulation of glucose transporters:** Increased GLUT-4 expression enhances glucose uptake by peripheral tissues.

These mechanisms complement conventional antidiabetic drugs and provide multi-targeted therapy with potentially fewer side effects.

5. Pharmacological Evidence

5.1 *Gymnema sylvestre*

Gymnemic acids are the main bioactive compounds. Preclinical studies show:
Enhanced insulin secretion
Suppression of intestinal glucose absorption
β-cell regeneration
Clinical trials (200-400 mg/day standardized extract) demonstrated reductions in fasting glucose and postprandial glucose levels.

5.2 *Curcuma longa* (Curcumin)

Curcumin has anti-inflammatory and antioxidant properties that improve insulin sensitivity.
Meta-analyses report reductions in fasting glucose (~15 mg/dL) and HbA1c (~0.5%) over 8-12 weeks.
Nano- and phytosomal formulations improve bioavailability.

5.3 *Momordica charantia*

Bioactive compounds: charantin, vicine, polypeptide-P.
Animal studies show insulin-mimetic effects.
Human trials in prediabetic and diabetic populations show moderate reductions in fasting glucose and improved glucose tolerance.

5.4 *Trigonella foenum-graecum*

Seeds contain galactomannan fiber and 4-hydroxyisoleucine.

Delays carbohydrate absorption and improves insulin receptor activity.
Clinical studies report reductions in fasting glucose (~15%) and HbA1c (~0.6%) over 8-12 weeks.

5.5 *Tinospora cordifolia* and *Pterocarpus marsupium*

Exhibits β-cell protection, antioxidant, and anti-inflammatory effects.
Preclinical studies demonstrate improved insulin secretion and glucose homeostasis.
Limited clinical evidence suggests beneficial effects on glycemic indices.

5.6 Summary Table of Clinical Evidence

Table 1: Clinical Studies on the Hypoglycemic Effects of Selected Indian Botanicals

Herb	Study Type	Dose	Duration	Outcome	Reference
Gymnema sylvestre	RCT	200-400 mg/day	8 weeks	↓ Fasting & postprandial glucose	[1]
Curcuma longa	Meta-analysis	500-1000 mg/day	8-12 weeks	↓ Fasting glucose & HbA1c	[2]
Momordica charantia	RCT	2 g/day juice	12 weeks	↓ Fasting glucose	[3]
Trigonella foenum-graecum	RCT	10 g/day seed powder	12 weeks	↓ Fasting glucose & HbA1c	[4]
Tinospora cordifolia	Pilot clinical	300 mg/day	8 weeks	Improved glycemic indices	[5]
Pterocarpus marsupium	Pilot clinical	500 mg/day	12 weeks	↓ Fasting glucose	[6]

6. Discussion

Indian medicinal herbs offer multi-mechanistic approaches to glycemic control. Preclinical evidence is robust, but clinical trials are often limited by small sample sizes, heterogeneous extract preparations, and short durations. Standardization of extracts, pharmacokinetic profiling, and well-designed randomized controlled trials are essential for clinical translation. Integrating traditional knowledge with modern pharmacology may lead to safer, culturally acceptable, and evidence-based antidiabetic therapies.

7. Future Prospects

Standardization and quality control of herbal extracts
Dose-finding and long-term safety studies.
Multicenter, randomized controlled trials.
Ethical compliance and biodiversity regulations.s
Integration with conventional therapies and AYUSH guidelines.
Transparent reporting and trial registration.

8. Conclusion

Indian medicinal herbs represent a promising resource for antidiabetic therapy. Combining traditional knowledge with rigorous scientific evaluation can yield reproducible, evidence-based interventions. Standardization, pharmacovigilance, and clinical validation remain critical to unlock their full potential.

References

1. Sharma M, Gupta V, Kalra S. Indian J Endocrinol Metab. 2023;27(2):89-97.
2. Chaudhury A, *et al*. Clin Diabetes. 2021;39(2):162-174.
3. Patwardhan B, Mashelkar RA. Drug Discov Today. 2020;25(10):1826-1832.
4. Modak M, *et al*. J Clin Biochem Nutr. 2022;71(1):15-31.
5. Khan A, *et al*. Front Pharmacol. 2023;14:1159073.
6. Additional studies on clinical trials as listed in the table above.